Subtilisin

A serine endopeptidase isolated from Bacillus subtilis. It hydrolyzes proteins with broad specificity for peptide bonds, and a preference for a large uncharged residue in P1. It also hydrolyzes peptide amides. (From Enzyme Nomenclature, 1992) EC 3.4.21.62.

Networked: 284 relevant articles (14 outcomes, 24 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Seidah, Nabil G: 11 articles (12/2013 - 04/2005)
2.	Varret, Mathilde: 8 articles (09/2014 - 08/2004)
3.	Boileau, Catherine: 7 articles (09/2014 - 08/2004)
4.	Abifadel, Marianne: 7 articles (09/2014 - 08/2004)
5.	Krempf, Michel: 7 articles (06/2014 - 08/2004)
6.	Stein, Evan A: 6 articles (12/2015 - 06/2012)
7.	Li, Jian-Jun: 6 articles (04/2015 - 12/2013)
8.	Xu, Rui-Xia: 6 articles (04/2015 - 12/2013)
9.	Costet, Philippe: 6 articles (01/2013 - 08/2004)
10.	Kastelein, John J P: 5 articles (06/2015 - 06/2014)

Related Diseases

1.	Hypercholesterolemia 01/01/2015 - "Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors have emerged as a novel treatment option in patients with hypercholesterolemia. " 06/01/2015 - "Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials." 05/01/2015 - "Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia." 09/01/2014 - "This analysis evaluated the effect of a monoclonal antibody to proprotein convertase subtilisin/kexin 9, alirocumab 150 mg every 2 weeks (Q2W), on Lp(a) levels in pooled data from 3 double-blind, randomized, placebo-controlled, phase 2 studies of 8 or 12 weeks' duration conducted in patients with hypercholesterolemia on background lipid-lowering therapy (NCT01266876, NCT01288469, and NCT01288443). " 03/01/2015 - "Alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9, is in Phase III development for the treatment of hypercholesterolemia. "
2.	Cardiovascular Diseases (Cardiovascular Disease) 10/27/2015 - "Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: A New Therapeutic Mechanism for Reducing Cardiovascular Disease Risk." 09/15/2015 - "Over the last decade, inhibition of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) has emerged as a promising target to reduce residual cardiovascular disease risk. " 04/01/2015 - "Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as an attractive therapeutic target for cardiovascular disease. " 01/01/2013 - "Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a novel biomarker of LDL clearance and a therapeutic target of cardiovascular disease. " 06/01/2012 - "Here we tested the hypothesis that ENaC is regulated by proprotein convertase subtilisin/kexin type 9 (PCSK9), a protease that modulates the risk of cardiovascular disease. "
3.	Hyperlipidemias (Hyperlipidemia) 11/01/2015 - "Bococizumab is a humanized monoclonal IgG2Δa antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) for the treatment of hyperlipidemia. " 06/01/2011 - "The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications." 01/01/2015 - "Proprotein convertase subtilisin/kexin type 9 (encoded by PCSK9) plays a well-known role in the regulation of low-density lipoprotein (LDL) receptors, and an inhibitor of this enzyme is a promising new therapeutic for hyperlipidemia. " 04/01/2015 - "Proprotein convertase subtilisin/kexin type 9 (PCSK9), a newly-identified member that plays an essential role in cholesterol homeostasis and holds decent promise for hyperlipidemia and coronary artery disease (CAD) treatment. " 02/01/2015 - "Inhibition of proprotein convertase subtilisin/kexin type 9: a novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia."
4.	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 05/01/2015 - "In this article, we will briefly review familial hypercholesterolemia and the role of proprotein convertase subtilisin/kexin 9 inhibitors in this condition. " 05/01/2015 - "The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia." 11/01/2014 - "Identification of the proprotein convertase subtilisin/kexin type 9 (PCSK9) as the third gene causing familial hypercholesterolemia (FH) and understanding its complex biology has led to the discovery of a novel class of therapeutic agents. " 09/01/2014 - "Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation." 11/05/2013 - "Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia."
5.	Dyslipidemias (Dyslipidemia) 06/01/2015 - "Potential blockbuster therapies, such as proprotein convertase subtilisin/kexin type 9 inhibitors, are expected to revolutionize dyslipidemia treatment and raise global sales. " 12/01/2013 - "Proprotein convertase subtilisin/kexin type 9 (PCSK9) and LDL lowering in the contemporary management of dyslipidemia." 11/01/2013 - "Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia." 03/01/2015 - "Inhibitors of proprotein convertase subtilisin kexin type 9 (PCSK9) represent a new therapeutic category of drugs for the treatment of dyslipidemia and atherosclerotic cardiovascular disease. " 10/15/2013 - "Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis."

Related Drugs and Biologics

1.	Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)
2.	LDL Receptors (LDL Receptor)
3.	Cholesterol
4.	LDL Cholesterol
5.	Serine Proteases (Serine Protease)
6.	Lipoproteins (Lipoprotein)
7.	Antibodies
8.	Oxidoreductases
9.	Fibrinogen (Factor I)
10.	Fluorescein (Funduscein)

Related Therapies and Procedures

1.	Cardiac Resynchronization Therapy
2.	Drug-Eluting Stents
3.	Bariatric Surgery
4.	Implantable Defibrillators (Implantable Cardioverter-Defibrillator)
5.	Denervation